Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
04-06 September, 2025
Not Confirmed
Not Confirmed
08-11 September, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
04-06 September, 2025
Industry Trade Show
Not Confirmed
08-11 September, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds
27 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-favorable-and-differentiated-pharmacokinetic-profile-of-asc30-oral-once-daily-tablet-in-its-us-phase-ib-multiple-ascending-dose-study-302540456.html
17 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-the-combination-of-asc47-and-asc31-its-dual-glp-1rgipr-peptide-agonist-demonstrated-significantly-greater-weight-loss-compared-to-the-combination-of-asc47-and-tirzepatide-in-an-animal-model-of-obesity-302531465.html
12 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-asc47-a-muscle-preserving-weight-loss-drug-candidate-for-treatment-of-obesity-demonstrated-greater-efficacy-with-tirzepatide-than-semaglutide-in-a-preclinical-model-302527869.html
06 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-completes-enrollment-in-us-phase-iia-study-for-its-small-molecule-oral-glp-1r-agonist-asc30-in-participants-with-obesity-or-overweight-302521917.html
28 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-first-participants-with-obesity-or-overweight-dosed-in-its-us-12-week-phase-iia-study-evaluating-once-monthly-subcutaneous-depot-formulation-of-small-molecule-glp-1r-agonist-asc30-302514495.html
14 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-completes-dosing-of-all-participants-in-its-us-clinical-study-combining-adipose-targeted-once-monthly-injectable-small-molecule-thr-agonist-asc47-and-semaglutide-for-the-treatment-of-obesity-302504315.html
ABOUT THIS PAGE